July 14, 2021
Takeda CFO Costa Saroukos Takeda Pharmaceutical is anticipating a delay in biosimilar entry for its blockbuster inflammatory bowel disease medicine Entyvio (vedolizumab) in Europe from the initially expected May 2024 date, CFO Costa Saroukos revealed at an investor event on...read more